Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey

被引:10
|
作者
Kaur, Sukhpal [1 ]
Singh, Ajay [2 ]
Saini, Sushma [1 ]
Rohilla, Latika [1 ]
Kaur, Jasvir [1 ]
Chandi, Anadeep [3 ]
Kaur, Gurpreet [1 ]
Singh, Manjeet [9 ]
Kumar, Pramod [1 ]
Soni, Shiv Lal [10 ]
Kajal, Kamal [2 ]
Naik, Naveen B. [2 ]
Malhotra, Pankaj [4 ]
Verma, Sanjay [5 ]
Gupta, Madhu [6 ]
Devnani, Mahesh [7 ]
Das, Karobi [1 ]
Pandav, S. S. [8 ]
Puri, G. D. [2 ]
机构
[1] Govt Multispecial Hosp, Natl Inst Nursing Educ, Dept Nursing, Chandigarh, India
[2] Govt Multispecial Hosp, Dept Anaesthesia & Intens Care, Chandigarh, India
[3] Govt Multispecial Hosp, Dept Obstet & Gynaecol, Chandigarh, India
[4] Govt Multispecial Hosp, Dept Internal Med, Chandigarh, India
[5] Govt Multispecial Hosp, Dept Paediat, Chandigarh, India
[6] Govt Multispecial Hosp, Dept Community Med, Chandigarh, India
[7] Govt Multispecial Hosp, Hosp Adm, Chandigarh, India
[8] Multispecial Hosp, Postgrad Inst Med Educ & Res, Ophthalmol, Chandigarh, India
[9] Govt Multispecial Hosp, Dept Med, Chandigarh, India
[10] Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Sect 12, Chandigarh 160012, India
关键词
Adverse events; ChAdOx1; nCoV-19; coronavirus disease 2019; healthcare professionals; side effects; vaccination;
D O I
10.4103/ijmr.ijmr_1221_21
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background & objectives: The safety of the ChAdOx1 nCoV-19 vaccine is a cause of concern for many who have been vaccinated. The people have multiple concerns and fear regarding the adverse events of the vaccine. Thus, this study was undertaken to establish the safety profile of ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) among the healthcare professionals. Methods: This was a descriptive cross-sectional survey. After taking clearance from the institutional ethics committee 1500 healthcare professionals, who had their vaccination in the past two weeks were selected. They were provided with an online survey proforma regarding adverse events following immunization (AEFIs) of COVID-19 vaccine developed using google forms with an informed consent form affixed to it. Results: A total of 1036 individuals participated in the study. The mean and median (inter quartile range) age of the participants was 37.7 +/- 11.25 and 35 (29-46) yr, respectively. Of these, 52.1 per cent were female, 29.3 per cent were doctors, 33.4 per cent were nurses and 9.5 per cent were paramedical staff. Forty six per cent participants experienced one or more minor AEFIs such as pain, tenderness, redness, etc. at the injection site. Fatigue (31.75%), generalized feeling of unwell (28.57%), muscle pain (23.16%) and fever (21.71%) were the most commonly reported systemic AEFIs followed by headache (20.07%), dizziness (10.03%) and joint pains (15.25%). Most of them experienced these AEFIs within 24 h of the first dose of administration. About 42 per cent of the participants took oral antipyretics/analgesics for managing the AEFIs. Interpretation & conclusions: ChAdOx1 nCoV-19 Corona Virus Vaccine was found to be associated with mild local and systemic AEFIs that were more common after the first dose as compared to the second dose. There adverse events could be dealt with oral over-the-counter medications, with no requirement of hospitalization.
引用
收藏
页码:123 / 128
页数:6
相关论文
共 50 条
  • [31] Prevalence of Covishield COVID-19 Vaccine (ChAdOx1 nCoV-19) Adverse Effects among Health Care Workers in Sri Lanka
    Manilgama, S. R.
    Hettiarachchi, N. M.
    Jayasinghe, K. I.
    De Silva, S.
    Wanigaratne, T.
    Jayalath, T.
    Bandusiri, R. P.
    Suganthan, N.
    Sudarshan, P.
    Pathirage, M.
    Rajaratnam, N.
    Senaratne, G.
    Rajapaksha, V.
    Wickramasinghe, A.
    Kulaweera, M. T. D.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 116 : S61 - S61
  • [32] Prevalence and determinants of adverse events following ChAdOx1 nCoV-19 vaccination (COVISHIELD) - A retrospective cohort study among healthcare workers in central Karnataka, India
    Davalagi, Shubha B.
    Nayak, Vaman P.
    Ghose, Anisha
    Marakatti, Siddarth S.
    Kasturi, Eshwar S.
    Maganahalli, Anurupa S.
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2023, 12 (11) : 2869 - 2874
  • [33] Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study
    Hammad, Noha M.
    Kadry, Heba M.
    Malek, Mai M.
    Bahgat, Shereen Mohamed
    Abdelsalam, Noha M.
    Afifi, Amira Hamed Mohamed
    Abo-alella, Doaa Alhussein
    VACCINES, 2022, 10 (10)
  • [34] Incidence of COVID-19 among individuals vaccinated with ChAdOx1 nCoV-19 vaccine (recombinant) against SARS-CoV-2 at a tertiary health care centre in Telangana
    Kokiwar, Prashant Ramdas
    Reddy, Bhadra
    Reddy, Preeti
    Gowrav, Siddappa
    Shirole, Chandrakant
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2022, 155 (01) : 211 - 213
  • [35] Incidence, Pattern and Severity of Adverse Events Following Immunization (AEFIs) Associated With Chadox1 nCOV-19 Corona Virus Vaccine (Recombinant) Among the Healthcare Workers of a Tertiary Care Institute of Eastern Uttar Pradesh, India
    Kamble, Bhushan
    Abu Bashar, Md
    Mishra, Chandra Pati
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (02)
  • [36] Symptoms and Side Effects of the ChAdOx1 nCoV-19 vaccine (AZD1222) among healthcare workers: A Single Center Experience
    Javed, Dawood
    Alharbi, Yazeed Hadi
    Javed, Abdullah
    Iqbal, Javed
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (12): : 3202 - 3204
  • [37] Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey
    Cherian, Somy
    Paul, Aby
    Ahmed, Sakir
    Alias, Bazil
    Manoj, Manesh
    Santhosh, Ansu K.
    Varghese, Delcey Rachel
    Krishnan, Narayanan
    Shenoy, Padmanabha
    RHEUMATOLOGY INTERNATIONAL, 2021, 41 (08) : 1441 - 1445
  • [38] Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey
    Somy Cherian
    Aby Paul
    Sakir Ahmed
    Bazil Alias
    Manesh Manoj
    Ansu K. Santhosh
    Delcey Rachel Varghese
    Narayanan Krishnan
    Padmanabha Shenoy
    Rheumatology International, 2021, 41 : 1441 - 1445
  • [39] Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea
    Bae, Seongman
    Lee, Yun Woo
    Lim, So Yun
    Lee, Ji Hyang
    Lim, Joon Seo
    Lee, Sojeong
    Park, Soyeon
    Kim, Sun Kyung
    Lim, Young Ju
    Kim, Eun Ok
    Jung, Jiwon
    Kwon, Hyouk Soo
    Kim, Tae Bum
    Kim, Sung Han
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2021, 36 (17) : 1 - 9
  • [40] Serious adverse events following immunization after ChAdOx1 nCov-19 vaccination in India: a single center experience
    Maurya, Miteshkumar Rajaram
    Ravi, Renju
    Pushparajan, Libby
    PAN AFRICAN MEDICAL JOURNAL, 2021, 40